Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Sponsor study identifier
Secondary identifiers
OTHER · NCI-CTRP Clinical Trials Registry
interventional
120
1 country
1
Study Start
February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
June 30, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 30, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 30, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 20, 2026
Actual (reported)August 24, 2026
Actual (reported)February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 30, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 30, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Through study completion; an average of 1 year.
Participants will be enrolled into one of three cohorts based on their sarcoma subtype. Relapsed/refractory ES or DSRCT are assigned to receive one of several predetermined cohort-specific investigational therapies.
MD Anderson Cancer Center
Houston, Texas, 77090, United States
Joseph Ludwig, MD
M.D. Anderson Cancer Center
First Submitted
August 20, 2026
First Posted
August 24, 2026
Study Start
February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
June 30, 2031
EstimatedEflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 30, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 24, 2026
Record last verified: 2026-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source retrieved: